The better progression-free survival and improved overall response rate observed in EML4-ALK V1 versus EML4-ALK V3 NSCLC patients in response to ALK TKIs treatment is in keeping with these findings (20, 43). The gene discussed is ALK; the disease is non-small cell lung carcinoma.